compass pathways is a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health. our first major initiative is developing psilocybin therapy through late-stage clinical trials in the eu and us for patients with treatment-resistant depression. we are developing psychoactive care pathways based on advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
Company profile
Ticker
CMPS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Compass Rx Ltd.
SEC CIK
CMPS stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
8 Apr 24
DEF 14A
Definitive proxy
8 Apr 24
PRE 14A
Preliminary proxy
28 Mar 24
8-K
Departure of Directors or Certain Officers
28 Mar 24
8-K
Compass Pathways Announces Fourth Quarter 2023 Financial Results
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
S-8
Registration of securities for employees
5 Jan 24
8-K
Compass Pathways appoints Teri Loxam as Chief Financial Officer
7 Dec 23
8-K
COMPASS Pathways Announces Third Quarter 2023 Financial Results
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
Transcripts
CMPS
Earnings call transcript
2023 Q2
3 Aug 23
CMPS
Earnings call transcript
2023 Q1
11 May 23
CMPS
Earnings call transcript
2022 Q4
28 Feb 23
CMPS
Earnings call transcript
2022 Q3
6 Nov 22
CMPS
Earnings call transcript
2022 Q2
4 Aug 22
CMPS
Earnings call transcript
2022 Q1
10 May 22
CMPS
Earnings call transcript
2021 Q4
24 Feb 22
CMPS
Earnings call transcript
2021 Q3
9 Nov 21
CMPS
Earnings call transcript
2021 Q2
11 Aug 21
CMPS
Earnings call transcript
2021 Q1
13 May 21
Latest ownership filings
4
George Jay Goldsmith
18 Apr 24
4
Ekaterina Malievskaia
18 Apr 24
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
11 Apr 24
4
George Jay Goldsmith
2 Apr 24
4
Ekaterina Malievskaia
2 Apr 24
4
Ekaterina Malievskaia
1 Apr 24
4
George Jay Goldsmith
1 Apr 24
4
George Jay Goldsmith
14 Mar 24
4
Ekaterina Malievskaia
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 248.37 mm | 248.37 mm | 248.37 mm | 248.37 mm | 248.37 mm | 248.37 mm |
Cash burn (monthly) | (no burn) | (no burn) | 11.35 mm | 10.89 mm | 5.69 mm | 9.57 mm |
Cash used (since last report) | n/a | n/a | 75.43 mm | 72.36 mm | 37.78 mm | 63.61 mm |
Cash remaining | n/a | n/a | 172.94 mm | 176.01 mm | 210.59 mm | 184.76 mm |
Runway (months of cash) | n/a | n/a | 15.2 | 16.2 | 37.0 | 19.3 |
Institutional ownership, Q3 2023
67.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 116 |
Opened positions | 32 |
Closed positions | 13 |
Increased positions | 20 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 163.24 bn |
Total shares | 41.59 mm |
Total puts | 186.50 k |
Total calls | 619.10 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
ATAI ATAI Life Sciences | 9.44 mm | $309.87 mm |
TCG Crossover GP I | 5.79 mm | $47.69 mm |
TCG Crossover Management | 3.86 mm | $28.55 bn |
Vivo Opportunity Fund | 3.22 mm | $26.50 mm |
ARK Investment Management | 2.43 mm | $18.00 bn |
Vivo Capital | 1.61 mm | $11.90 bn |
Citadel Advisors | 1.57 mm | $11.59 bn |
Paradigm Biocapital Advisors | 1.36 mm | $10.05 bn |
Ra Capital Management | 1.29 mm | $9.52 bn |
Agf Management | 1.02 mm | $7.56 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 24 | Goldsmith George Jay | Ordinary Shares | Sell | Dispose S | Yes | Yes | 8.7841 | 10,850 | 95.31 k | 3,973,400 |
17 Apr 24 | Goldsmith George Jay | Ordinary Shares | Sell | Dispose S | No | Yes | 8.7841 | 10,850 | 95.31 k | 3,975,673 |
17 Apr 24 | Ekaterina Malievskaia | Ordinary Shares | Sell | Dispose S | Yes | Yes | 8.7841 | 10,850 | 95.31 k | 3,975,673 |
17 Apr 24 | Ekaterina Malievskaia | Ordinary Shares | Sell | Dispose S | No | Yes | 8.7841 | 10,850 | 95.31 k | 3,973,400 |
16 Apr 24 | Goldsmith George Jay | Ordinary Shares | Sell | Dispose S | Yes | Yes | 8.5289 | 23,880 | 203.67 k | 3,984,250 |
16 Apr 24 | Goldsmith George Jay | Ordinary Shares | Sell | Dispose S | No | Yes | 8.5289 | 23,881 | 203.68 k | 3,986,523 |
16 Apr 24 | Ekaterina Malievskaia | Ordinary Shares | Sell | Dispose S | Yes | Yes | 8.5289 | 23,881 | 203.68 k | 3,986,523 |
16 Apr 24 | Ekaterina Malievskaia | Ordinary Shares | Sell | Dispose S | No | Yes | 8.5289 | 23,880 | 203.67 k | 3,984,250 |
1 Apr 24 | Goldsmith George Jay | Ordinary Shares | Sell | Dispose S | Yes | Yes | 8.9579 | 25,750 | 230.67 k | 4,008,130 |
1 Apr 24 | Goldsmith George Jay | Ordinary Shares | Sell | Dispose S | No | Yes | 8.9579 | 25,750 | 230.67 k | 4,010,404 |
News
Cantor Fitzgerald Reiterates Overweight on Compass Pathways
18 Apr 24
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
17 Apr 24
Who's Who In Cannabis: Latest Executive Changes You Should Know About
15 Apr 24
Micron, Iris Energy, Trip.com Group And Other Big Stocks Moving Higher On Monday
1 Apr 24
Morgan Stanley Initiates Coverage On Compass Pathways with Overweight Rating, Announces Price Target of $30
1 Apr 24
Press releases
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
1 Apr 24
Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024
22 Feb 24
Compass Pathways to participate in upcoming Oppenheimer investor conference
31 Jan 24
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
24 Jan 24